Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IBRX
IBRX | US
7.18
USD-0.05
-0.69%
IBRX | US
About IBRX
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
03/06/2026
Close
7.18
Open
7.23
High
7.30
Low
7.03
ImmunityBio Inc. a clinical-stage biotechnology company engages in developing therapies and vaccines that complement harness and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms including antibody cytokine fusion protein N-803 vaccine technologies toll-Like receptor activating adjuvants natural killer cells and damage-associated molecular patterns inducers. The company also develops therapeutic agents which are in Phase II or III clinical trial for the treatment of liquid and solid tumors including bladder pancreatic and lung cancers as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris Inc.; and license agreements with LadRx Corporation GlobeImmune Inc. Access to Advanced Health Institute 3M Innovative Properties Company Sanford Health Shenzhen Beike Biotechnology Co. Ltd. Sorrento Therapeutics Inc. and Viracta Therapeutics Inc. The company is based in San Diego California.
View LessIBRX | US
Risk
78.5
Sharpe
1.55
Luna's Score
54/100
Recommendation
Hold
Luna says (IBRX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
72.8%1 month
78.5%3 months
94.5%6 months
134.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
-
Debt to equity
-1.43
Debt to assets
2.25
Ent. to EBITDA
-8.99
Ent. to rev.
2.23K
PEG
-
Other Fundamentals
EBITDA
-341.06M
MarketCap
5.00B
MarketCap(USD)
5.00B
Div. yield
-
Op. margin
-9.49K
Erngs. growth
-
Rev. growth
2.45K
Ret. on equity
-
Short ratio
18.91
Short perc.
32.65
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.62
Range1M
1.67
Range3M
3.05
Volumes: Market Activity
Rel. volume
0.59
Price X volume
63.67M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -8.99 | - | Cheaper |
| Ent. to Revenue | 2,227.59 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | - | 15.55 | - |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 94.52 | - | Riskier |
| Debt to Equity | -1.43 | -1.23 | Cheaper |
| Debt to Assets | 2.25 | 0.25 | Expensive |
| Market Cap | 5.00B | - | Market Leader |
